Xanthine oxidase-IN-5
Modify Date: 2025-08-25 06:16:05
Xanthine oxidase-IN-5 structure
|
Common Name | Xanthine oxidase-IN-5 | ||
|---|---|---|---|---|
| CAS Number | 2276711-87-4 | Molecular Weight | 341.34 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H16FN3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Xanthine oxidase-IN-5Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable drug-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model[1]. |
| Name | Xanthine oxidase-IN-5 |
|---|
| Description | Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable drug-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.70 μM (XO)[1] |
| In Vivo | Xanthine oxidase-IN-5 (compound 9m) shows potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate[1]. Animal Model: Potassium oxonate-induced hyperuricemic rat model[1] Dosage: 20 mg/kg Administration: PO; single (measured serum uric acid after 0.5 - 8 hours) Result: Showed potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate. |
| References |
| Molecular Formula | C18H16FN3O3 |
|---|---|
| Molecular Weight | 341.34 |